Abstract:Sequence signatures of multidonor broadly neutralizing influenza antibodies can be used to quantify the prevalence of B cells with virus-neutralizing potential to accelerate development of broadly protective vaccine strategies. Antibodies of the same class share similar recognition modes and developmental pathways, and several antibody classes have been identified that neutralize diverse group 1- and group 2-influenza A viruses and have been observed in multiple human donors. One such multidonor antibody class, the HV6-1-derived class, targets the stem region of hemagglutinin with extraordinary neutralization breadth. Here, we use an iterative process to combine informatics, biochemical, and structural analyses to delineate an improved sequence signature for HV6-1-class antibodies. Based on sequence and structure analyses of known HV6-1 class antibodies, we derived a more inclusive signature (version 1), which we used to search for matching B-cell transcripts from published next-generation sequencing datasets of influenza vaccination studies. We expressed selected antibodies, evaluated their function, and identified amino acid-level requirements from which to refine the sequence signature (version 2). The cryo-electron microscopy structure for one of the signature-identified antibodies in complex with hemagglutinin confirmed motif recognition to be similar to known HV6-1-class members, MEDI8852 and 56.a.09, despite differences in recognition-loop length. Threading indicated the refined signature to have increased accuracy, and signature-identified heavy chains, when paired with the light chain of MEDI8852, showed neutralization comparable to the most potent members of the class. Incorporating sequences of additional class members thus enables an improved sequence signature for HV6-1-class antibodies, which can identify class members with increased accuracy.

Proteomic analysis of influenza haemagglutinin-specific antibodies following vaccination reveals convergent immunoglobulin variable region signatures.

Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination

Identification and Analysis of B Cell Epitopes of Hemagglutinin of H1N1 Influenza Virus.

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements.

Multiplexed Antibody Sequencing and Profiling of the Human Hemagglutinin-specific Memory B Cell Response following Influenza Vaccination

Intra-seasonal Antibody Repertoire Analysis of a Subject Immunized with an MF59®-adjuvanted Pandemic 2009 H1N1 Vaccine.

Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric states

Bioinformatic Analysis of Antibody Repertoire Development in Response to Influenza Vaccination

Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans

Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human Neutralizing Antibodies against Influenza A Viruses

Identification of different hemagglutinin isoforms of influenza A virus H1N1.

Structural Mapping of Polyclonal IgG Responses to HA After Influenza Virus Vaccination or Infection

Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin

H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination.

Characterization and Analysis of VH1-2-encoded Heterosubtypic Antibodies Isolated from an Avian H5N1 Patient

Immunogenic Stimulus for Germline Precursors of Antibodies That Engage the Influenza Hemagglutinin Receptor-Binding Site.

Applying Unique Molecular Identifiers in Next Generation Sequencing Reveals a Constrained Viral Quasispecies Evolution under Cross-Reactive Antibody Pressure Targeting Long Alpha Helix of Hemagglutinin

H1N1 Influenza Virus Epitopes Classified by Monoclonal Antibodies.

Vaccine-Induced Antibodies That Neutralize Group 1 and Group 2 Influenza A Viruses.

Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses